About arvinas inc. - ARVN
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.
ARVN At a Glance
Arvinas, Inc.
5 Science Park
New Haven, Connecticut 06511
| Phone | 1-203-535-1456 | Revenue | 262.60M | |
| Industry | Biotechnology | Net Income | -80,800,000.00 | |
| Sector | Health Technology | Employees | 246 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
ARVN Valuation
| P/E Current | 58.541 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 3.202 |
| Price to Book Ratio | 1.736 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.50 |
| Enterprise Value to Sales | 0.627 |
| Total Debt to Enterprise Value | 0.055 |
ARVN Efficiency
| Revenue/Employee | 1,067,479.675 |
| Income Per Employee | -328,455.285 |
| Receivables Turnover | 41.031 |
| Total Asset Turnover | 0.29 |
ARVN Liquidity
| Current Ratio | 4.917 |
| Quick Ratio | 4.917 |
| Cash Ratio | 4.81 |
ARVN Profitability
| Gross Margin | 98.02 |
| Operating Margin | -43.755 |
| Pretax Margin | -30.655 |
| Net Margin | -30.769 |
| Return on Assets | -8.932 |
| Return on Equity | -16.231 |
| Return on Total Capital | -18.239 |
| Return on Invested Capital | -15.989 |
ARVN Capital Structure
| Total Debt to Total Equity | 2.097 |
| Total Debt to Total Capital | 2.054 |
| Total Debt to Total Assets | 1.268 |
| Long-Term Debt to Equity | 1.659 |
| Long-Term Debt to Total Capital | 1.625 |